Zum Inhalt springen
Home » Nanobiotix: Progress in NBTXR3 Development Collaboration

Nanobiotix: Progress in NBTXR3 Development Collaboration

NANOBIOTIX, a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced updates to its corporate strategy designed to enable long-term growth in view of significant progress in the Company’s collaboration for the co-development and global commercialization of lead therapeutic candidate NBTXR3.

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
LabNews Media LLC

LabNews Media LLC

The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They are bestselling authors, science writers and science journalists since 1994.More details about their writing on X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu